- Home
- CANF vs EVGN Comparison
CANF vs EVGN Comparison
Compare CANF & EVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- EVGN
- Stock Information
- Founded
- CANF 1994
- EVGN 1999
- Country
- CANF Israel
- EVGN Israel
- Employees
- CANF N/A
- EVGN N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- EVGN Agricultural Chemicals
- Sector
- CANF Health Care
- EVGN Industrials
- Exchange
- CANF Nasdaq
- EVGN Nasdaq
- Market Cap
- CANF 9.4M
- EVGN 9.7M
- IPO Year
- CANF N/A
- EVGN N/A
- Fundamental
- Price
- CANF $1.81
- EVGN $1.42
- Analyst Decision
- CANF Strong Buy
- EVGN Strong Buy
- Analyst Count
- CANF 2
- EVGN 1
- Target Price
- CANF $14.00
- EVGN $12.00
- AVG Volume (30 Days)
- CANF 122.9K
- EVGN 21.1K
- Earning Date
- CANF 03-04-2025
- EVGN 03-06-2025
- Dividend Yield
- CANF N/A
- EVGN N/A
- EPS Growth
- CANF N/A
- EVGN N/A
- EPS
- CANF N/A
- EVGN N/A
- Revenue
- CANF $667,000.00
- EVGN $7,478,000.00
- Revenue This Year
- CANF $409.56
- EVGN $90.35
- Revenue Next Year
- CANF N/A
- EVGN $38.71
- P/E Ratio
- CANF N/A
- EVGN N/A
- Revenue Growth
- CANF N/A
- EVGN 30.69
- 52 Week Low
- CANF $1.29
- EVGN $1.20
- 52 Week High
- CANF $4.69
- EVGN $10.40
- Technical
- Relative Strength Index (RSI)
- CANF 64.57
- EVGN 42.28
- Support Level
- CANF $1.45
- EVGN $1.44
- Resistance Level
- CANF $1.50
- EVGN $1.55
- Average True Range (ATR)
- CANF 0.12
- EVGN 0.09
- MACD
- CANF 0.05
- EVGN -0.01
- Stochastic Oscillator
- CANF 66.67
- EVGN 17.41
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About EVGN Evogene Ltd
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules and genetic elements as the core components for such products. It holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment followed by Industry.